Furthermore, treatment with the ROS inhibitor N-acetyl cysteine (L-NAC) led to a more significant reduction in CD71 expression in IKE-treated TIPE2−/− tumor MDSCs compared to IKE-treated WT tumor MDSCs (Figure 3e and Figure S3b). Here, TFRC is linked to neoplasm.